On August 15, 2024, the U.S. Food and Drug Administration (FDA) approved durvalumab (IMFINZI®, AstraZeneca) in combination with platinum-containing chemotherapy for use as neoadjuvant treatment, followed by single-agent durvalumab as adjuvant therapy, in adults with resectable non-small cell lung cancer (NSCLC). This approval applies to patients with tumors measuring 4 cm or greater and/or node-positive … Continue reading FDA Approves Durvalumab / IMFINZI® for Resectable NSCLC Non-Small Cell Lung Cancer